Advances in oncology have been instrumental in improving outcomes of patients with cancer. CART cellular therapies have arguably changed the way we care for hematologic malignancies forever, but the logistics of administering CART have challenged how applicable this therapy could be to all eligible patients.
I sit down with the amazing Dr. Navneet Majhail, Director of Bone & Marrow Transplant at the Cleveland Clinic and President of the Society of Marrow Transplantation 2019-2020 and discuss logistics of CART administration and what can be done to mitigate barriers to successful therapy. You want to listen to this one if you have any interest in CART, and how can you not.